
Clairity Breast becomes the first FDA-authorized AI software to predict five-year breast cancer risk using routine mammography images.
Key Details
- 1FDA grants de novo authorization to Clairity Breast, developed by Boston-based Clairity.
- 2The AI tool analyzes mammogram images for subtle features correlated with future cancer risk.
- 3Unlike traditional models, Clairity Breast does not require age or genetic data.
- 4The system was trained on millions of mammogram images linked to five-year outcomes.
- 5Clairity Breast delivers validated risk scores to radiologists through standard clinical systems.
- 6Commercial launch is targeted for the end of 2025.
Why It Matters

Source
Radiology Business
Related News

Hybrid AI Approach Cuts Mammography Workload by 38%
A Dutch research team demonstrated that a 'hybrid' AI strategy can reduce radiologist workload in mammography screening by nearly 40% without affecting performance.

Former US Surgeon General Jerome Adams Joins Eko as Medical Advisor
Former US Surgeon General Jerome Adams has joined Eko Health as a distinguished medical advisor to support AI-powered cardiac and pulmonary detection technologies.

Hybrid AI-Human Mammography Reading Cuts Workload Without Compromising Cancer Detection
A hybrid AI and radiologist reading strategy for screening mammography reduced radiologist workload by 38% without affecting recall or cancer detection rates.